Zoetis Cuts Top-End Sales Outlook as US Pet Business Weakens, Yet Raises Profit Target
The animal health group's US dog and cat franchise shrank 8% in the third quarter, dragging group sales slightly lower even as livestock and overseas sales grew.
Zoetis posted third-quarter 2026 revenue of $2.4bn on 5 November, about 1% below the same quarter a year earlier. The company said a weaker US companion animal business outweighed gains elsewhere in the group.
Sales of products for US pets fell 8%. Zoetis pointed to three pressures: price sensitivity among pet owners, competition in dermatology, and generic products. The livestock and international businesses both grew in the period, partly cushioning the shortfall.
Looking ahead, the company tightened its full-year revenue guidance to a range of $9.22bn to $9.32bn, while lifting its adjusted earnings-per-share outlook to $6.25 to $6.35. The material available does not explain what is driving the profit upgrade relative to the sales picture.
Zoetis also highlighted several regulatory developments. The US Food and Drug Administration approved Convenia RTU for Dogs in October, and the agency granted an Emergency Use Authorization for Simparica Trio against New World screwworm in dogs. The company also cited several approvals outside the US, though details of those were not available.
By way of context, an Emergency Use Authorization allows a product to be used under defined conditions to meet an urgent need. It is not the same as a full marketing approval.
Why it matters
- US companion animal demand is the weak spot: Zoetis cites pricing sensitivity, dermatology competition and generics as the sources of the 8% decline.
- Guidance moved in opposite directions, with a narrower revenue range and a higher adjusted EPS range, so the quarter's softness did not change the company's profit outlook.
- The screwworm authorisation for Simparica Trio is conditional and emergency-based, so its scope and terms are worth checking before assuming commercial impact.
- Livestock and international growth, plus several ex-US approvals, show revenue support outside the US pet market.
Company's press release (SEC filing): Zoetis Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
